Background/Aims: In patients with primary renal diseases the current knowledge of hyperglycemia associated with corticosteroid therapy is limited. We therefore examined the prevalence and risk factors of glucocorticoid-induced diabetes mellitus (DM) in primary renal diseases. Methods: Patients were recruited with primary renal diseases who were started on corticosteroids between April 2002 and June 2005. In patients with DM, an impaired fasting glucose level and/or positive urinary glucose analyses before corticosteroids therapy were excluded. Results: During corticosteroid therapy (initial dose: prednisolone 0.75 ± 0.10 mg/kg/day), DM was newly diagnosed in 17 (40.5%) of 42 patients. All of the 17 patients were diagnosed as having DM by postprandial hyperglycemia at 2 h after lunch, although they had normal fasting blood glucose levels. Age (OR 1.40, 95% CI 1.06–1.84) and body mass index (OR 1.87, 95% CI 1.03–3.38) were determined as independent risk factors for glucocorticoid-induced DM. Conclusion: Over 40% of patients with primary renal disease developed DM during treatment with corticosteroids. A high age and high body mass index are the independent risk factors for glucocorticoid-induced DM. 24-hour urinary glucose analyses and postprandial plasma glucose are useful for detecting glucocorticoid-induced DM.

1.
Hirsch IB, Paauw DS: Diabetes management in special situations. Endocrinol Metab Clin North Am 1997;26:631–645.
2.
Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115–123.
3.
Panthakalam S, Bhatnagar D, Klimiuk P: The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139–141.
4.
Lentine KL, Brennan DC, Schnitzler MA: Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005;16:496–506.
5.
Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97–101.
6.
Schiel R, Heinrich S, Steiner T, Ott U, Stein G: Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005;9:164–169.
7.
Hoogwerf B, Danese RD: Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489–505.
8.
Benhamou PY, Penforinis A: Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab (Paris) 2002;28:166–175.
9.
Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T: The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389–396.
10.
Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPAR-γ stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861–866.
11.
Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345–351.
12.
Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983–988.
13.
Andrade IS, Monsalve RMC, Martinez De Hurtado E, Chacin LF, Caminos QR, Yupanqui H, Lopez G, De La Torre W: Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study. Pharmacology 2003;68:89–95.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.